Written and clinically reviewed by Dr Brendan Dias
Consultant Urologist & Robotic Surgeon · MBBS, MS (General Surgery), DrNB (Urology), IntFRCS (England), FUSANZ, FRACS (Urology)
Last clinically reviewed: 30 July 2026
Prostate cancer is the most commonly diagnosed cancer in Australian men, and in its early, curable stages it almost never causes symptoms. That is the case for PSA testing. It is also, however, a test that can lead to further investigation and to the diagnosis of cancers that would never have caused harm — which is why the decision to test is best made with information rather than by default. This guide explains what PSA measures, how results are interpreted, and what happens next.
What PSA Actually Measures
Prostate specific antigen is a protein made by prostate cells and released into the bloodstream. Any process that disturbs prostate tissue raises the level: cancer, but equally benign enlargement, prostatitis, urinary infection, recent instrumentation, ejaculation in the previous 48 hours and long cycling rides. This is why a single result is rarely acted on in isolation, and why an infection is treated and the test repeated before anyone talks about biopsy.
Who Should Consider Testing, and When
Australian guidance supports offering PSA testing every two years to men aged 50 to 69 who, after discussing the benefits and harms, choose to be tested. Men with a first-degree relative diagnosed with prostate cancer — and especially those with multiple affected relatives, a relative diagnosed young, or a known BRCA2 mutation — are usually advised to begin between 40 and 45. Testing is generally not recommended when life expectancy is less than about seven years, because a cancer found then is unlikely to shorten life while treatment could still cause side effects.
Interpreting the Result
Rather than one universal cut-off, urologists interpret PSA in context. Age-related ranges give a rough guide. PSA density — the PSA divided by prostate volume on imaging — distinguishes a level explained by a large benign prostate from one that is disproportionate. PSA velocity, the rate of rise across serial tests, matters more than any single reading. The free-to-total ratio can add information in borderline cases. A digital rectal examination is performed alongside, because a palpable abnormality is significant even with a normal PSA.
The MRI-First Pathway
Where PSA is persistently abnormal, multiparametric MRI is now performed before biopsy. Lesions are scored PI-RADS 1 to 5. A reassuring MRI combined with low PSA density may allow continued monitoring rather than biopsy, while a PI-RADS 4 or 5 lesion is targeted directly. This approach reduces unnecessary biopsies and improves the detection of clinically significant disease relative to systematic biopsy alone.
If a Biopsy Is Needed
Dr Dias performs transperineal prostate biopsy, sampling through the skin of the perineum rather than through the rectum. This route has a very low risk of serious infection compared with the older transrectal technique, and gives better access to the anterior prostate. Samples are taken both systematically and targeted to the MRI lesion. Blood in the urine or semen for a few weeks afterwards is expected and harmless.
What a Diagnosis Means — and Doesn't Mean
Not every prostate cancer needs treating. Low-risk disease is frequently managed with active surveillance: regular PSA, repeat MRI and periodic biopsy, with treatment triggered only if the cancer shows signs of progression. For intermediate and high-risk disease, curative options include robotic radical prostatectomy — including Retzius-sparing and nerve-sparing techniques — and radiation therapy. A fuller overview is available on the prostate cancer treatment page.
Weighing Benefits Against Harms
The benefit of PSA testing is finding aggressive cancer while it is still confined to the prostate and curable. The harms are anxiety from false positives, the small risks of biopsy, and overdiagnosis of indolent cancers. MRI-first pathways and active surveillance have meaningfully reduced these harms over the past decade, but they have not removed them — which is why an informed conversation with your GP or urologist remains the right starting point.
Frequently Asked Questions
What is a PSA test?
PSA (prostate specific antigen) is a protein produced by prostate cells and measured with a simple blood test. It is organ-specific but not cancer-specific: levels rise with prostate cancer, but also with benign prostatic enlargement, prostatitis, urinary infection, recent catheterisation, vigorous cycling and ejaculation. A PSA result is therefore a starting point for assessment rather than a diagnosis in itself.
At what age should Australian men consider PSA testing?
Australian guidance supports offering PSA testing to men aged 50 to 69 who decide, after being informed of the benefits and harms, that they wish to be tested — typically every two years. Men with a first-degree relative diagnosed with prostate cancer, and particularly those with several affected relatives or a known BRCA2 mutation, may be advised to start from around age 40 to 45. Testing is generally not recommended where life expectancy is under about seven years.
What is a normal PSA level?
There is no single normal value. Age-related reference ranges are commonly used — broadly under 2.5 ng/mL in the forties, under 3.5 in the fifties and under 4.5 in the sixties — but interpretation also depends on prostate size, the rate of change over time (PSA velocity), the free-to-total PSA ratio and the findings on examination. A result within range does not entirely exclude cancer, and a raised result usually has a benign explanation.
Does a raised PSA mean I have prostate cancer?
No. Most men with a mildly elevated PSA do not have prostate cancer. Benign prostatic enlargement is the commonest cause, followed by inflammation or infection of the prostate. The usual next step is to repeat the test after several weeks, treating any infection first, and to interpret the result alongside a digital rectal examination. Persistently raised or rising levels lead to further imaging rather than straight to biopsy.
What happens after an abnormal PSA result?
A repeat PSA confirms the abnormality, then a multiparametric MRI of the prostate is usually arranged. MRI is scored using the PI-RADS system from 1 to 5; low scores with reassuring PSA density may allow continued monitoring rather than biopsy, while higher scores guide a targeted biopsy to the suspicious area. This MRI-first pathway reduces unnecessary biopsies and improves detection of clinically significant cancer.
What does a prostate biopsy involve?
Modern biopsy is usually performed transperineally — through the skin between the scrotum and anus — rather than through the rectum, which substantially reduces the risk of serious infection. Samples are taken systematically and targeted to any MRI-identified lesion, under local anaesthetic with sedation or under general anaesthetic. Common after-effects include blood in the urine or semen for a few weeks and mild discomfort.
What are the risks and downsides of PSA testing?
The main harms are false positives leading to anxiety and further tests, and overdiagnosis — finding low-risk cancers that would never have caused harm, which can lead to unnecessary treatment and side effects. These risks are reduced, but not eliminated, by MRI-first pathways and by using active surveillance for low-risk disease. The benefit is earlier detection of aggressive cancers at a curable stage.
Should I stop testing at a certain age?
Screening is about life expectancy rather than a fixed birthday. Prostate cancer detected in a man unlikely to live another seven to ten years is unlikely to affect his lifespan, so routine PSA testing is generally not recommended in that situation. Men in excellent health in their seventies may still reasonably choose to test after discussing it with their doctor. Symptomatic men are assessed regardless of age.
Do urinary symptoms mean I should have a PSA test?
Urinary symptoms such as a weak stream, frequency and nocturia are far more often caused by benign prostatic enlargement than by cancer, because most prostate cancers grow in the peripheral zone and cause no symptoms until advanced. A PSA test is still reasonable as part of assessing those symptoms, since the result influences both cancer risk assessment and choice of BPH treatment.
Where can I have PSA testing and prostate assessment in Melbourne?
Your GP can arrange the initial PSA test and refer you if the result needs further assessment. Dr Brendan Dias reviews men with elevated or rising PSA at consulting rooms in Maribyrnong and Bundoora, coordinating multiparametric MRI and, when indicated, transperineal prostate biopsy, with results discussed alongside all management options including active surveillance.
The Bottom Line
PSA testing is a decision, not a routine. For most Australian men aged 50 to 69 — and earlier where there is a family history — a two-yearly test, interpreted in context and followed by MRI rather than reflex biopsy, offers the best balance between catching aggressive cancer early and avoiding unnecessary treatment.